Ultrasmall Fe3O4 and Gd2O3 hybrid nanoparticles for T1-weighted MR imaging of cancer

Cancer Nanotechnology

Research

S. Kamran Kamrava¹  Mehri Mirrahimi²  Jaber Beik²  Zahra Alamzadeh²  Rasoul Irajirad²  Abolfazl Sarikhani³  Samideh Khoei³  Vahid Pirhajati Mahabadi⁴  Habib Ghaznavi⁵ 

[1] ENT and Head & Neck Research Center and Department, The Five Senses Health Institute, Hazrat Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran;Finetech in Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran;Finetech in Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran;Medical Physics Department, Iran University of Medical Sciences, Tehran, Iran;Neuroscience Research Center, Iran University of Medical Sciences, Tehran, Iran;Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran;

关键词: T;    Tumor diagnosis;    Hybrid nanoparticles;    Contrast agents;    Ultrasmall iron oxide nanoparticles;   

DOI  :  10.1186/s12645-022-00148-5

 received in 2022-08-17, accepted in 2022-11-28,  发布年份 2022

来源: Springer

【 摘 要 】

Gadolinium-based contrast agents (GdCAs) have been the most frequently used T1-weighted magnetic resonance imaging (MRI) contrast agents for decades. However, they have serious disadvantages such as low longitudinal relaxivity value (r1) and high dose associated-nephrotoxicity that restrict their wide applications. These emphasize the need for an ideal stable and biocompatible T1-weighted CA with high contrast enhancement performance. Here, we propose a wet-chemical synthesis technique to form a nanocomposite consisting of ultrasmall iron oxide nanoparticles (US-IO) and Gd2O3 hybrid nanoparticles stabilized with dextran (FG-HNPs) for T1-weighted MR imaging. Relaxometry study showed that FG-HNPs have a high r1 value (42.28 mM−1S−1) and low relaxivity ratio (r2/r1: 1.416) at 3.0T. In vivo MRI contrast enhancement factor (ΔSNR) for FG-HNPs (257.025 ± 17.4%) was found to be 1.99-fold higher than US-IO (129.102 ± 15%) and 3.35-fold higher than Dotarem (76.71 ± 14.2%) as routinely used T1-weighted CA. The cytotoxicity assay and histological examination confirmed the biocompatibility of FG-HNPs. The biodistribution study, transmission electron microscopy (TEM) and Prussian blue (PB) staining of tumor tissue proved the effective tumor localization of FG-HNPs. Therefore, FG-HNPs can be suggested as a promising CA for T1-weighted MRI of tumors by virtue of their remarkable relaxivities and high biocompatibility.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

Fig. 6

Fig. 1

13690_2022_1011_Article_IEq2.gif

40644_2022_507_Article_IEq1.gif

Fig. 2

12902_2022_1244_Article_IEq24.gif

12902_2022_1244_Article_IEq8.gif

12982_2022_119_Article_IEq178.gif